Recruiting

BBT002 Safety and Effects in COPD and Healthy Volunteers

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

BBT002

+ Placebo

Drug
Who is being recruted

Chronic Disease+5

+ Lung Diseases

+ Lung Diseases, Obstructive

From 18 to 75 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 1
Interventional
Study Start: September 2025
See protocol details

Summary

Principal SponsorBambusa Therapeutics
Study ContactTracy Ji, Study Director
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 5, 2025

Actual date on which the first participant was enrolled.

This study explores a new treatment called BBT002, aiming to see how safe it is and how it behaves in the body. The research involves both healthy volunteers and individuals with Chronic Obstructive Pulmonary Disease (COPD), a condition that makes it hard to breathe. Understanding the effects of BBT002 could lead to better treatments for those suffering from COPD, potentially easing their symptoms and improving their quality of life. The study is significant because it addresses the need for more effective COPD treatments. Participants in the study will receive BBT002 in two parts. In the first part, healthy volunteers will take a single dose, while in the second part, those with COPD will receive two repeated doses. Researchers will monitor participants closely, looking for any side effects and measuring changes in heart activity, blood tests, and overall health through physical exams. The study aims to gather detailed information on any adverse events and how the body responds to BBT002, including changes in vital signs like blood pressure and heart rate.

Official TitleA Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)
Principal SponsorBambusa Therapeutics
Study ContactTracy Ji, Study Director
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

68 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseLung DiseasesLung Diseases, ObstructivePathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsDisease AttributesPulmonary Disease, Chronic Obstructive

Criteria

Inclusion Criteria:( A\&B) 1. Age of 18-65 years (HVs), 35-75 years (patients) 2. Body mass index between 18-32 kg/m², capped at 120 kg 3. Negative pregnancy tests for women of childbearing potential 4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit 5. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers 6. Adequate contraception use (for men and women of childbearing potential) 7. No clinically significant abnormalities or history of relevant diseases Key Inclusion Criteria (Part B only) 1. Documented history of COPD with a post-bronchodilator FEV1/FVC \< 0.70 2. FEV1 ≥ 50% and FEV1\<80% predicted at screening. Exclusion Criteria:( part A \& B) 1. Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV) 2. Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections 3. History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders 4. Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function 5. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1 6. Abnormal Electrocardiogram(ECG) findings 7. History of drug/alcohol abuse in the past 2 years 8. History of severe allergic reactions or hypersensitivity Key Exclusion Criteria for (Part B only) 1. Current diagnosis of other significant pulmonary disease 2. Significant or unstable cardiovascular diseases 3. Recent clinically significant infection 4. Inability to perform spirometry

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

4 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
A single dose of BBT002 will be administered in healthy volunteers

Group II

Experimental
Two doses of BBT002 will be administered in patients with COPD.

Group III

Placebo
A single dose of Placebo will be administered in healthy volunteers.

Group IV

Placebo
Two doses of Placebo will be administered in patients with COPD.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 11 locations

Recruiting

The Second Hospital of Anhui Medical Univesity

Hefei, ChinaOpen The Second Hospital of Anhui Medical Univesity in Google Maps
Recruiting soon

The third affiliated hosptial of Guangzhou Medical University

Guangzhou, China
Suspended

The First Affiliated Hospital of Guangdong Medical University

Guangzhou, China
Recruiting soon

Jiangmen Central Hospital

Jiangmen, China
Recruiting
11 Study Centers
BBT002 Safety and Effects in COPD and Healthy Volunteers | PatLynk